ROCKVILLE, Md., Sept. 6, 2017 /PRNewswire/ -- CASI
Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company
dedicated to innovative therapeutics addressing cancer and other
unmet medical needs announces it will present at the 19th Annual
Rodman & Renshaw Global Investment Conference, sponsored by
H.C. Wainwright & Co.,
LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace
Hotel in New York City.
Event: 19th Annual Rodman & Renshaw Global Investment
Conference
Date: Monday, September 11,
2017
Time: 3:25-3:50 PM (Eastern
Time)
Presenter: Alexander A. Zukiwski,
MD
Location: Holmes I; Lotte New York Palace Hotel in
New York City
A copy of the presentation materials will be made available
directly through the Investor Relations section of the company's
website, www.casipharmaceuticals.com, on September 11, 2017.
About CASI Pharmaceuticals, Inc.
CASI is a U.S. based, late-stage biopharmaceutical company
focused on the acquisition, development and commercialization of
innovative therapeutics addressing cancer and other unmet medical
needs for the global market with a focus on commercialization in
China. CASI's product pipeline
features (1) EVOMELA®, MARQIBO® and
ZEVALIN®, all U.S. Food and Drug Administration (FDA)
approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for
China regional rights, and
currently in various stages of the regulatory process for market
approval in China, (2) proprietary
drug candidate, ENMD-2076, ongoing in one Phase 2 clinical study,
and (3) CASI-001 and CASI-002, proprietary preclinical candidates
in immuno-oncology. CASI is headquartered in Rockville, Maryland and has a wholly owned
subsidiary and R&D operations in Beijing, China. More information on CASI is
available at www.casipharmaceuticals.com and in CASI's filings
with the U.S. Securities and Exchange Commission.
Forward Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act with
respect to the outlook for expectations for future financial or
business performance, strategies, expectations and goals.
Forward looking statements are subject to numerous assumptions,
risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to
update forward-looking statements is assumed. Actual results
could differ materially from those currently anticipated due to a
number of factors, including: that we may be unable to continue as
a going concern as a result of our inability to raise sufficient
capital for our operational needs; the volatility in the market
price of our common stock; risks relating to interests of our
largest stockholders that differ from our other stockholders; the
risk of substantial dilution of existing stockholders in future
stock issuances, the difficulty of executing our business strategy
in China; our inability to predict
when or if our product candidates will be approved for marketing by
the China Food and Drug Administration authorities; our inability
to enter into strategic partnerships for the development,
commercialization, manufacturing and distribution of our proposed
product candidates or future candidates; risks relating to the need
for additional capital and the uncertainty of securing additional
funding on favorable terms; risks associated with our product
candidates; risks associated with any early-stage products under
development; the risk that results in preclinical and early
clinical models are not necessarily indicative of later clinical
results; uncertainties relating to preclinical and clinical trials,
including delays to the commencement of such trials; the lack of
success in the clinical development of any of our products;
dependence on third parties; and risks relating to the
commercialization, if any, of our proposed products (such as
marketing, safety, regulatory, patent, product liability, supply,
competition and other risks). Such factors, among others,
could have a material adverse effect upon our business, results of
operations and financial condition. We caution readers not to
place undue reliance on any forward-looking statements, which only
speak as of the date made. Additional information about the factors
and risks that could affect our business, financial condition and
results of operations, are contained in our filings with the U.S.
Securities and Exchange Commission, which are available at
www.sec.gov.
EVOMELA®, MARQIBO® and
ZEVALIN® are proprietary to Spectrum
Pharmaceuticals, Inc. and its affiliates.
COMPANY
CONTACT:
CASI Pharmaceuticals,
Inc.
240.864.2643
ir@casipharmaceuticals.com
|
INVESTOR
CONTACT:
Torrey Hills
Capital
Jim
Macdonald
858.456.7300
jm@sdthc.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-present-at-the-annual-rodman--renshaw-global-investment-conference-300514136.html
SOURCE CASI Pharmaceuticals, Inc.